Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

RECRUITING

NCT05504057

Antihistamines, Amantadine and Evolution of COVID-19

Sponsor: Consorci Sanitari de Terrassa

View on ClinicalTrials.gov

Summary

The rates of symptomatic COVID19 infection, hospital admission among COVID19 cases and survival would be quantified in patiens chronically treated with antihistamines or amantadine, with the aim of determining the role of antihistamines and amantadine in the evolution of COVID19.

Official title: Evaluation of Treatments With Antihistamines and Amantadine in the Evolution of the SARS-CoV-2 Infection

Key Details

Gender

All

Age Range

Any - Any

Study Type

OBSERVATIONAL

Enrollment

140660

Start Date

2020-03-01

Completion Date

2028-02-24

Last Updated

2026-04-03

Healthy Volunteers

Yes

Conditions

COVID-19

Interventions

DRUG

Antihistamine

Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and postcovid syndrome and thrombosis among patients previously treated with antihistamines

DRUG

Amantadine

Observation of the rate of COVID19 infection, the rate of hospitalization, the rate of survival and the rate of postcovid syndrome and thrombosis among patients previously treated with amantadine

Locations (2)

Hospital de Terrassa

Terrassa, Barcelona, Spain

Hospital of Terrassa